drugset / Trial / NCT02329769
Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see whether PRO044 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 44 in the DNA for the dystrophin protein.
Timeline
- Start
- 2014-12
- Primary completion
- 2016-07-01
- Completion
- 2016-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRO044 | Unknown | 6 mg/kg | Subcutaneous |
| Subject | PRO044 | Unknown | 9 mg/kg | Subcutaneous |